Objectives: This study aims to examine the relationship of serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) levels withinterleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), fetuin-A, insulin, homeostatic model assessment (HOMA)-insulin resistance (IR), and diseaseactivity in patients with rheumatoid arthritis (RA) who are in remission or have low disease activity.Patients and methods: Fifty-four patients with RA (8 males, 46 females; mean age 52.7±12.3 years; range 40 to 64 years) and 34 healthy controls (6males, 28 females; mean age 53.2±11.3 years; range 41 to 65 years) were included in the study. The sTWEAK, fetuin-A, insulin, lipid profile and IL-6concentrations were determined. The HOMA-IR levels were calculated using a calculator. Disease activity score 28 was used to assess the diseaseactivity.Results: The erythrocyte sedimentation rate, C-reactive protein, fetuin-A, and IL-6 levels were higher in the RA group than in the control group(p=0.004, 0.001, 0.001, and 0.003, respectively). sTWEAK levels were lower in the RA group than in the control group (p=0.007). There were nodifferences in the TNF-α, HOMA-IR, insulin, and lipid profile levels of the two groups (p>0.05). sTWEAK had a negative correlation with body massindex and fetuin-A (r=-0.261 and r=-0.287, respectively).Conclusion: We found that RA patients had lower sTWEAK levels and higher fetuin-A levels than the control group subjects. Furthermore, thesetwo molecules were associated with each other. This study demonstrated that in RA patients, even if the disease is controlled with treatment,some molecules associated with an increased metabolic and cardiovascular risk continue to function. Follow-up studies on larger populations arewarranted to confirm these findings.